Relay Therapeutics (RLAY) Net Income towards Common Stockholders (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$73.2 million in Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$73.2 million, up 4.95% year-over-year; the trailing twelve-month figure through Mar 2026 was -$271.9 million (up 18.44% YoY), and the FY2025 annual result was -$275.7 million, up 18.36% from the prior year.
• Net Income towards Common Stockholders fell to -$73.2 million in Q1 2026 per RLAY's latest filing, from -$54.9 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$54.9 million in Q4 2025 and troughed at -$98.5 million in Q2 2023.
• A 5-year average of -$77.6 million and a median of -$76.8 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders surged 60.29% in 2022, then tumbled 51.89% in 2023.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$67.5 million in 2022, then fell by 23.74% to -$83.5 million in 2023, then rose by 8.97% to -$76.0 million in 2024, then advanced by 27.74% to -$54.9 million in 2025, then slumped by 33.35% to -$73.2 million in 2026.
• Business Quant data shows RLAY's Net Income towards Common Stockholders at -$73.2 million in Q1 2026, -$54.9 million in Q4 2025, and -$74.0 million in Q3 2025.